Please Wait.....
Report
Mantle Cell Lymphoma Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Diagnosis (Laboratory exams, Imaging Tests, Bone marrow Biopsy, Others), By Treatment (Diagnosis {Imaging Tests, Surgical Examination, Others}, Therapy{Chemotherapy, Targeted therapy, Immunotherapy, Stem Cell Transplantation, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region and Competition, 2020-2030F
Market Report I 2025-05-16 I 185 Pages I TechSci Research
Market Overview
The Global Mantle Cell Lymphoma Market was valued at USD 2.53 billion in 2024 and is projected to reach USD 3.97 billion by 2030, growing at a CAGR of 7.80% during the forecast period. Mantle cell lymphoma (MCL), a rare and aggressive subtype of non-Hodgkin lymphoma, is characterized by the abnormal proliferation of B lymphocytes within the lymphatic system. Although MCL accounts for a small proportion of overall lymphoma cases, its rapid progression and limited curative treatment options make it a significant clinical concern. Recent years have seen substantial advancements in the field, particularly with the emergence of targeted therapies and immunotherapies aimed at improving patient outcomes. Traditional methods, such as chemotherapy and stem cell transplantation, have shown restricted long-term success, prompting a shift towards more specific and less toxic treatments. Notable breakthroughs include the introduction of Bruton's tyrosine kinase (BTK) inhibitors and phosphoinositide 3-kinase (PI3K) inhibitors, which interfere with critical pathways that sustain MCL cell survival and proliferation. These innovations are reshaping therapeutic strategies and expanding the market potential for MCL treatments.
Key Market Drivers
Advancements in Targeted Therapies
Technological progress in targeted therapies is a major catalyst for growth in the global mantle cell lymphoma market. MCL, known for its resistance to conventional treatments, has seen a significant transformation with the development of targeted approaches like BTK inhibitors, including ibrutinib, which specifically disrupt the BTK signaling protein that promotes tumor cell survival. These therapies have shown marked improvements in progression-free survival and patient quality of life, thereby attracting growing attention from healthcare providers and industry stakeholders. Additionally, PI3K inhibitors offer an alternative for patients not responding to BTK therapies, further diversifying the treatment landscape. The advancement of combination regimens, integrating multiple targeted agents, also holds promise for enhancing therapeutic efficacy and minimizing resistance. These innovations, supported by biomarker research and genetic profiling, are enabling more personalized treatment protocols and reinforcing the expansion of the MCL market.
Key Market Challenges
Heterogeneity of Disease
The complexity and variability of mantle cell lymphoma present a critical challenge to its clinical management and market growth. MCL encompasses a wide spectrum of disease behaviors-from indolent to highly aggressive subtypes-making it difficult to standardize treatment approaches. The diversity in disease progression among patients necessitates personalized therapy plans, which increases the difficulty of creating one-size-fits-all treatment models. Furthermore, the genetic heterogeneity of MCL tumors complicates drug development, as different mutations and molecular subtypes respond variably to treatment. This also hampers clinical trial design, as many studies focus on specific patient segments, limiting the generalizability of results across the broader MCL population.
Key Market Trends
Rising Investments and Funding
Increased investment and funding are playing a pivotal role in propelling the growth of the mantle cell lymphoma market. With the emergence of promising therapies, the MCL segment has attracted substantial attention from pharmaceutical companies, venture capitalists, and institutional investors. This surge in financial backing is accelerating research and development efforts, facilitating the introduction of innovative therapies and expanding access to advanced treatment options. Alongside private investment, public grants and nonprofit initiatives are also bolstering academic research, patient support services, and advocacy efforts. These combined financial inputs are enhancing manufacturing capabilities, supporting awareness campaigns, and strengthening the overall ecosystem for MCL treatment and management.
Key Market Players
- Kite Pharma, Inc. (Gilead Sciences, Inc.)
- F. Hoffman La Roche Ltd
- Abbvie, Inc.
- Celgene Corporation
- Eli Lilly and Company
- Amgen, Inc.
- Takeda Pharmaceutical Co. Ltd
- AstraZeneca Plc
- Johnson and Johnson Services Inc.
- BeiGene GmBH
Report Scope:
In this report, the Global Mantle Cell Lymphoma Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Mantle Cell Lymphoma Market, By Diagnosis:
o Laboratory Exams
o Imaging Tests
o Bone Marrow Biopsy
o Others
- Mantle Cell Lymphoma Market, By Treatment:
o Diagnosis
o Therapy
- Mantle Cell Lymphoma Market, By End User:
o Hospitals & Clinics
o Ambulatory Care Centers
o Others
- Mantle Cell Lymphoma Market, By Region:
o North America
United States
Canada
Mexico
o Europe
France
United Kingdom
Italy
Germany
Spain
o Asia-Pacific
China
India
Japan
Australia
South Korea
o South America
Brazil
Argentina
Colombia
o Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Mantle Cell Lymphoma Market.
Available Customizations:
Global Mantle Cell Lymphoma Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Global Mantle Cell Lymphoma Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Diagnosis (Laboratory exams, Imaging Tests, Bone marrow Biopsy, Others)
4.2.2. By Treatment (Diagnosis {Imaging Tests, Surgical Examination, Others}, Therapy{Chemotherapy, Targeted therapy, Immunotherapy, Stem Cell Transplantation, Others)
4.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
4.2.4. By Region
4.2.5. By Company (2024)
4.3. Market Map
4.3.1. By Diagnosis
4.3.2. By Treatment
4.3.3. By End User
4.3.4. By Region
5. Asia Pacific Mantle Cell Lymphoma Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Diagnosis
5.2.2. By Treatment
5.2.3. By End User
5.2.4. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China Mantle Cell Lymphoma Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Diagnosis
5.3.1.2.2. By Treatment
5.3.1.2.3. By End User
5.3.2. India Mantle Cell Lymphoma Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Diagnosis
5.3.2.2.2. By Treatment
5.3.2.2.3. By End User
5.3.3. Australia Mantle Cell Lymphoma Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Diagnosis
5.3.3.2.2. By Treatment
5.3.3.2.3. By End User
5.3.4. Japan Mantle Cell Lymphoma Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Diagnosis
5.3.4.2.2. By Treatment
5.3.4.2.3. By End User
5.3.5. South Korea Mantle Cell Lymphoma Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Diagnosis
5.3.5.2.2. By Treatment
5.3.5.2.3. By End User
6. Europe Mantle Cell Lymphoma Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Diagnosis
6.2.2. By Treatment
6.2.3. By End User
6.2.4. By Country
6.3. Europe: Country Analysis
6.3.1. France Mantle Cell Lymphoma Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Diagnosis
6.3.1.2.2. By Treatment
6.3.1.2.3. By End User
6.3.2. Germany Mantle Cell Lymphoma Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Diagnosis
6.3.2.2.2. By Treatment
6.3.2.2.3. By End User
6.3.3. Spain Mantle Cell Lymphoma Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Diagnosis
6.3.3.2.2. By Treatment
6.3.3.2.3. By End User
6.3.4. Italy Mantle Cell Lymphoma Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Diagnosis
6.3.4.2.2. By Treatment
6.3.4.2.3. By End User
6.3.5. United Kingdom Mantle Cell Lymphoma Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Diagnosis
6.3.5.2.2. By Treatment
6.3.5.2.3. By End User
7. North America Mantle Cell Lymphoma Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Diagnosis
7.2.2. By Treatment
7.2.3. By End User
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Mantle Cell Lymphoma Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Diagnosis
7.3.1.2.2. By Treatment
7.3.1.2.3. By End User
7.3.2. Mexico Mantle Cell Lymphoma Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Diagnosis
7.3.2.2.2. By Treatment
7.3.2.2.3. By End User
7.3.3. Canada Mantle Cell Lymphoma Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Diagnosis
7.3.3.2.2. By Treatment
7.3.3.2.3. By End User
8. South America Mantle Cell Lymphoma Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Diagnosis
8.2.2. By Treatment
8.2.3. By End User
8.2.4. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Mantle Cell Lymphoma Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Diagnosis
8.3.1.2.2. By Treatment
8.3.1.2.3. By End User
8.3.2. Argentina Mantle Cell Lymphoma Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Diagnosis
8.3.2.2.2. By Treatment
8.3.2.2.3. By End User
8.3.3. Colombia Mantle Cell Lymphoma Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Diagnosis
8.3.3.2.2. By Treatment
8.3.3.2.3. By End User
9. Middle East and Africa Mantle Cell Lymphoma Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Diagnosis
9.2.2. By Treatment
9.2.3. By End User
9.2.4. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Mantle Cell Lymphoma Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Diagnosis
9.3.1.2.2. By Treatment
9.3.1.2.3. By End User
9.3.2. Saudi Arabia Mantle Cell Lymphoma Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Diagnosis
9.3.2.2.2. By Treatment
9.3.2.2.3. By End User
9.3.3. UAE Mantle Cell Lymphoma Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Diagnosis
9.3.3.2.2. By Treatment
9.3.3.2.3. By End User
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions
12. Global Mantle Cell Lymphoma Market: SWOT Analysis
13. Porter's Five Forces Analysis
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Product
14. Competitive Landscape
14.1. Kite Pharma, Inc. (Gilead Sciences, Inc.)
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Financials (In case of listed)
14.1.5. Recent Developments
14.1.6. Key Personnel Details
14.1.7. SWOT Analysis
14.2. F. Hoffman La Roche Ltd
14.3. Abbvie, Inc.
14.4. Celgene Corporation
14.5. Eli Lilly and Company
14.6. Amgen, Inc.
14.7. Takeda Pharmaceutical Co. Ltd
14.8. AstraZeneca Plc
14.9. Johnson and Johnson Services Inc.
14.10. BeiGene GmBH
15. Strategic Recommendations
16. About Us & Disclaimer
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security